Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced an upcoming data presentation on etripamil at the ESC Congress 2024 in London on August 30, 2024. Professor John Camm will present patient-reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation.
The presentation, titled "Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303," will provide insights about patient experience, satisfaction, and disease management. Dr. David Bharucha, Chief Medical Officer at Milestone Pharmaceuticals, emphasized the importance of this data in understanding the self-administration of investigational etripamil nasal spray in a medically unsupervised setting.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) ha annunciato una prossima presentazione di dati su etripamil al Congresso ESC 2024 a Londra il 30 agosto 2024. Il Professor John Camm presenterà i dati sui risultati riportati dai pazienti del trial di fase 3 NODE-303 di etripamil per la tachicardia sopraventricolare parossistica (PSVT) in una presentazione poster moderata.
La presentazione, intitolata "Misure della Qualità della Vita con l'Auto-Administrazione di Etripamil per Episodi Acuti di Tachicardia Supraventricolare Parossistica in un Contesto Medico Non Supervisionato: Risultati Riportati dai Pazienti dal NODE-303," fornirà approfondimenti sull'esperienza dei pazienti, la soddisfazione e la gestione della malattia. Il Dr. David Bharucha, Direttore Medico di Milestone Pharmaceuticals, ha sottolineato l'importanza di questi dati per comprendere l'auto-somministrazione dello spray nasale investigazionale di etripamil in un contesto medico non supervisionato.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) anunció una próxima presentación de datos sobre etripamil en el Congreso ESC 2024 en Londres el 30 de agosto de 2024. El Profesor John Camm presentará los dátiles de resultados informados por los pacientes del ensayo de fase 3 NODE-303 de etripamil en taquicardia supraventricular paroxística (PSVT) en una presentación de poster moderada.
La presentación, titulada "Medidas de Calidad de Vida con Auto-Administración de Etripamil para Episodios Agudos de Taquicardia Supraventricular Paroxística en un Entorno Médico No Supervisado: Resultados Informados por los Pacientes del NODE-303," proporcionará información sobre la experiencia del paciente, la satisfacción y el manejo de la enfermedad. El Dr. David Bharucha, Director Médico de Milestone Pharmaceuticals, enfatizó la importancia de estos datos para entender la auto-administración del spray nasal investigacional de etripamil en un entorno médico no supervisado.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST)는 2024년 8월 30일 런던에서 열리는 ESC Congress 2024에서 etripamil에 대한 데이터 발표를 예정하고 있습니다. 존 캄 교수는 paroxysmal supraventricular tachycardia (PSVT)에 대한 NODE-303 3상 시험의 환자 보고 결과 데이터를 모더레이터가 있는 포스터 발표에서 소개할 것입니다.
발표 제목은 "의학적 감독이 없는 환경에서 급성 에피소드를 위한 Etripamil 자가 투여의 삶의 질 측정: NODE-303에서 환자가 보고한 결과"이며, 환자 경험, 만족도 및 질병 관리에 대한 통찰력을 제공합니다. Milestone Pharmaceuticals의 최고 의료 책임자인 David Bharucha 박사는 의학적으로 감독되지 않는 환경에서의 실험적 etripamil 비강 분무의 자가 투여 이해에서 이 데이터의 중요성을 강조했습니다.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a annoncé une prochaine présentation de données sur etripamil lors du Congrès ESC 2024 à Londres le 30 août 2024. Le Professeur John Camm présentera les données rapportées par les patients de l'
La présentation, intitulée "Mesures de qualité de vie avec auto-administration d'Etripamil pour des épisodes aigus de tachycardie supraventriculaire paroxystique dans un contexte médical non supervisé : résultats rapportés par les patients du NODE-303," fournira des informations sur l'expérience des patients, la satisfaction et la gestion de la maladie. Le Dr. David Bharucha, directeur médical de Milestone Pharmaceuticals, a souligné l'importance de ces données pour comprendre l'auto-administration du spray nasal investigational d'etripamil dans un contexte médical non supervisé.
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) hat eine bevorstehende Datenpräsentation zu etripamil auf dem ESC Congress 2024 in London am 30. August 2024 angekündigt. Professor John Camm wird in einer moderierten Posterpräsentation die patientenberichten Ergebnisse aus der NODE-303 Phase 3 Studie zu etripamil bei paroxysmaler supraventrikulärer Tachykardie (PSVT) vorstellen.
Die Präsentation mit dem Titel "Lebensqualitätsmessungen mit der Selbstadministration von Etripamil für akute Episoden der paroxysmalen supraventrikulären Tachykardie in einer medizinisch nicht überwachten Umgebung: Patientenberichtete Ergebnisse aus NODE-303" wird Einblicke in die Patientenerfahrung, Zufriedenheit und das Krankheitsmanagement geben. Dr. David Bharucha, Chief Medical Officer von Milestone Pharmaceuticals, betonte die Bedeutung dieser Daten für das Verständnis der Selbstadministration des investigationalen etripamil Nasensprays in einer medizinisch nicht überwachten Umgebung.
- None.
- None.
MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the annual meeting of the European Society of Cardiology, ESC Congress 2024 in London, United Kingdom on August 30, 2024. Professor John Camm will present patient reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation. The poster presentation will be available following the embargo at: https://MilestonePharma.com.
“We look forward to Professor Camm’s upcoming presentation at the ESC Congress 2024 on this important topic of PSVT and the self-administration of investigational etripamil nasal spray in a medically unsupervised setting,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer, Milestone Pharmaceuticals. “These patient-reported outcomes data, that will be presented, provide insights about patient experience, satisfaction, and disease management.”
ESC Presentation Details:
Moderated Poster Presentation Title:
Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303
Presenter:
John Camm, MD, Professor of Clinical Cardiology, St. George's University of London, United Kingdom
Date and time:
Friday, August 30, 2024, 13:00 – 13:50 BST
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications,
kfox@milestonepharma.com
Investor Relations
Chris Calabrese,
ccalabrese@lifesciadvisors.com
Kevin Gardner,
kgardner@lifesciadvisors.com
FAQ
What data will Milestone Pharmaceuticals (MIST) present at ESC Congress 2024?
Who will present the etripamil data for Milestone Pharmaceuticals (MIST) at ESC Congress 2024?
What is the title of Milestone Pharmaceuticals' (MIST) presentation at ESC Congress 2024?
When and where will Milestone Pharmaceuticals (MIST) present at ESC Congress 2024?
What is the focus of Milestone Pharmaceuticals' (MIST) etripamil study?
